文献速递肺外科

新辅助治疗后机器人辅助与胸腔镜肺叶切除术中转开胸的比较

Impact of Neoadjuvant Therapy, Tumor Size, and Surgical Approach on Conversion to Open Thoracotomy During Lobectomy.
PubMed 文献 · Ann Thorac Surg · 2026-03-31

基于2010—2022年全国住院数据,纳入3937例接受新辅助化疗免疫、化放疗或单纯化疗后行微创肺叶切除术的II–III期NSCLC患者,比较机器人辅助与VATS的中转开胸率及围术期结局。机器人组中转开胸率7.9%,VATS组17.2%,VATS独立相关于中转开胸(校正OR 1.98)。

要点

  • 新辅助治疗后微创肺叶切除术总体中转开胸率为13.1%。
  • 机器人辅助手术中转开胸率7.9%,低于VATS的17.2%。
  • VATS与中转开胸独立相关(校正OR 1.98,P<.001)。

核心结论

  • 接受新辅助治疗的肺癌患者中,超过1/10的微创肺叶切除术会中转开胸。
  • 与VATS相比,机器人辅助手术与中转开胸相对风险降低54%相关。

研究设计与样本

  • 基于2010—2022年全国医院层面数据的回顾性队列研究,纳入3937例II或III期NSCLC成人患者。
  • 患者接受新辅助化疗免疫治疗、化放疗或单纯化疗后行微创肺叶切除术,分为机器人组和VATS组。

主要发现

  • 3937例中515例(13.1%)中转开胸,化放疗后15.1%、单纯化疗后12.8%、化疗免疫治疗后9.6%(P<.001)。
  • 机器人手术1745例(44.3%),中转开胸137例(7.9%);VATS 2192例(55.7%),中转开胸378例(17.2%)(P<.001)。
  • VATS独立相关于中转开胸(校正OR 1.98;P<.001)。
  • 两组其他短期结局相似。

临床怎么用

  • 新辅助治疗后行微创肺叶切除术应预判中转开胸风险,机器人辅助可能降低中转率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant therapy options for non-small cell lung cancer (NSCLC) are increasingly used before minimally invasive resection. These operations are generally more challenging and have higher rates of conversion to open surgery. In this context, we compare perioperative outcomes of robotic and video-assisted thoracoscopic surgery (VATS) after neoadjuvant therapy. METHODS: We used national hospital-level data to identify adult patients diagnosed with stage II or III NSCLC undergoing minimally invasive lobectomy after neoadjuvant chemoimmunotherapy, chemoradiotherapy, or chemotherapy alone between 2010 and 2022. Patients were split into robotic and VATS cohorts. The primary outcome was conversion to open surgery, and secondary outcomes included lymph node yield, length of stay, readmission, and 30-day and 90-day mortality. Multivariable logistic and negative binomial regressions were created to account for patient demographics and tumor characteristics. RESULTS: Of 3937 patients fitting inclusion criteria, 515 (13.1%) were converted to open, including 15.1% after chemoradiotherapy, 12.8% after chemotherapy alone, and 9.6% after chemoimmunotherapy (P < .001). Robotic surgery was performed in 1745 patients (44.3%) with 137 (7.9%) conversions, and VATS was used in 2192 patients (55.7%) with 378 (17.2%) conversions (P < .001). VATS was independently associated with conversion to open thoracotomy (adjusted odds ratio, 1.98; P < .001). All other short-term outcomes were similar between groups. CONCLUSIONS: Conversions from minimally invasive to open surgery occur in >1 in 10 patients receiving neoadjuvant therapy for lung cancer. The robotic approach is associated with a 54% relative risk reduction in open conversions compared with VATS.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Pohlman A, Marten AD, Coughlin JM, et al. Impact of Neoadjuvant Therapy, Tumor Size, and Surgical Approach on Conversion to Open Thoracotomy During Lobectomy. Ann Thorac Surg. 2026. PMID: 41933782. doi:10.1016/j.athoracsur.2026.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。